<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6339437</article-id><article-id pub-id-type="publisher-id">2426</article-id><article-id pub-id-type="doi">10.1186/s12906-018-2426-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Preventive effects of a novel herbal mixture on atopic dermatitis-like skin lesions in BALB/C mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mechesso</surname><given-names>Abraham Fikru</given-names></name><address><email>afikru110@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seung-Jin</given-names></name><address><email>dvmlessj@naver.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Na-Hye</given-names></name><address><email>skyphn@naver.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jin-Yoon</given-names></name><address><email>mewrina@nate.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Im</surname><given-names>Zi-Eum</given-names></name><address><email>zium78@korea.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Suh</surname><given-names>Joo-Won</given-names></name><address><email>jwsuh@mju.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7188-1499</contrib-id><name><surname>Park</surname><given-names>Seung-Chun</given-names></name><address><phone>82-53-950- 19 5964</phone><email>parksch@knu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0661 1556</institution-id><institution-id institution-id-type="GRID">grid.258803.4</institution-id><institution>Laboratory of Veterinary Pharmacokinetics and Pharmacodynamics (LVPP), College of Veterinary Medicine, </institution><institution>Kyungpook National University, </institution></institution-wrap>41566, 80 Daehakro, Bukgu, Daegu, Republic of Korea </aff><aff id="Aff2"><label>2</label>Forest Resources Development Institute of Gyeongsangbuk-do, Andong, Gyeongsangbuk-do 36605 Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2339 0388</institution-id><institution-id institution-id-type="GRID">grid.410898.c</institution-id><institution>Center for Nutraceutical and Pharmaceutical Materials, Division of Bioscience and Bioinformatics, Science campus, </institution><institution>Myongji University, </institution></institution-wrap>449-728 Yongin, Gyeonggi Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>19</volume><elocation-id>25</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">A combination of parts of <italic>Cornus officinalis, Rosa multiflora, Lespedeza bicolor</italic>, <italic>Platycladus orientalis</italic>, and <italic>Castanea crenata</italic> is commonly used for alleviating inflammatory skin disorders. Therefore, this study was carried out to evaluate the in vitro and in vivo preventive effects of a novel herbal formula made from the five plants (C2RLP) against atopic dermatitis in BALB/C mice.</p></sec><sec><title>Methods</title><p id="Par2">Mice were allocated into five groups (<italic>n</italic>&#x02009;=&#x02009;8) including, control (Normal, petrolatum, and betamethasone treated) and treatment groups (treated with 2.5 and 5% C2RLP ointment). Atopic lesion was induced by applying 1-Chloro-2, 4-dinitrobenzene to the dorsal thoracic area of mice. Macroscopical and histological evaluations were performed to determine the effects of treatment on the progress of the skin lesions. The effects of treatment on the production and release of interleukins, interferon -&#x003d2;, nitrite, prostaglandin E2, thymus and activation-receptor chemokine, and &#x003b2;-hexosaminidase were evaluated and comparisons were made between groups. In addition, the chemical compounds present in C2RLP were identified by Liquid Chromatography-Mass Spectrometry.</p></sec><sec><title>Results</title><p id="Par3">Topical application of C2RLP reduced the dermatitis score and suppressed histopathological changes in mice. Treatment significantly reduced (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) plasma IL-4 level, the production of nitrite, prostaglandin E2, and thymus and activation-receptor chemokine production. The lipopolysaccharide-induced iNOS-mRNA expression in RAW 264.7 cells was also suppressed by high concentrations of C2RLP. In addition, C2RLP showed an inhibitory effect against DPPH free radical (IC<sub>50</sub>&#x02009;=&#x02009;147.5&#x02009;&#x003bc;g/ml) and &#x003b2;-hexosaminidase release (IC<sub>50</sub>&#x02009;=&#x02009;179.5&#x02009;&#x003bc;g/ml). Liquid Chromatography-Mass Spectrometry analysis revealed the presence of various compounds, including loganin, ellagic acid, and kaempferol 3-glucoside.</p></sec><sec><title>Conclusion</title><p id="Par4">Down-regulation of T- helper 2 cellular responses and suppression of inflammatory mediators contributed to the protective effects of C2RLP from atopic dermatitis in BALB/C mice.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atopic dermatitis</kwd><kwd>Inflammation</kwd><kwd>Mice</kwd><kwd>Skin</kwd></kwd-group><funding-group><award-group><funding-source><institution>Forest Resources Development Institute and Cooperative Research Program for Agriculture, Science and Technology, Korea</institution></funding-source><award-id>PJ01128901</award-id><principal-award-recipient><name><surname>Park</surname><given-names>Seung-Chun</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par16">Atopic dermatitis (AD) is an allergic skin disease characterized by complex symptoms such as drying and thickening of the skin, and scratch marks that are frequently associated with immunoglobulin-E (IgE) hyper-responsiveness to environmental allergens. The wrist, neck, face, and the crooks of the elbows and knees are among the most frequent locations of the lesions [<xref ref-type="bibr" rid="CR1">1</xref>]. AD is mostly affecting children with onset before the age of five years [<xref ref-type="bibr" rid="CR2">2</xref>]. Environmental (house dust mites and air pollution) and genetic factors considered the causes of AD. In addition, genetic predisposition accompanied by assorted peculiar immune symptom accounts for more than 50% of reported cases [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par17">Activation of T-helper 2 (Th2) and mast cells are mentioned in the development of AD [<xref ref-type="bibr" rid="CR4">4</xref>]. It is associated with an increase in serum concentration of Th2 cytokines, including interleukin (IL) -4, IL-5, IL-10, and IL-13. In addition, expression of interferon- &#x003b3; (IFN-&#x003b3;) is also reported in cases of AD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Basal keratinocytes produce thymus and activation-regulated chemokine (TARC) recruits Th2-lymphocytes and further aggravate dermatitis [<xref ref-type="bibr" rid="CR7">7</xref>]. Authors also suggested that the release of &#x003b2;-hexosaminidase from degranulated mast cells, high levels of serum immunoglobulin (Ig)E, and the expression of proinflammatory mediators such as prostaglandin E2 (PGE2) and nitrite (NO) are important determinants in the propensity of mice to AD [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par18">In spite of the profound side effects caused by topical steroids and oral anti-histamines, these drugs are commonly used to treat AD [<xref ref-type="bibr" rid="CR10">10</xref>]. Hence, efforts have been directed towards identifying safer and effective compounds of plant origin which can modulate the pathological mechanism(s) of AD such as anti-histamine effects, inhibition of Th<sub>2</sub> responses and IgE production [<xref ref-type="bibr" rid="CR11">11</xref>]. More than 20% of the population in Korea rely on traditional medicine as the primary health care [<xref ref-type="bibr" rid="CR12">12</xref>]. However, only a few studies have been conducted on the efficacy and safety of medicinal plants. Therefore, a screening test was conducted using the DPPH antioxidant, &#x003b2;-hexoseaminidase, and NO assay on 286 plants from Gyeongbuk Forest Resource Development Institute, Republic of Korea. These assays were selected as a screening method, taking into account the multifactorial nature of AD. Accordingly, <italic>Cornus officinalis</italic> (Family: Cornaceae), <italic>Castanea crenata</italic> (Family: Fagaceae), <italic>Rosa multiflora</italic> (Family: Cornaceae)<italic>, Lespedeza bicolor</italic> (Family: Legumes), and <italic>Platycladus orientalis</italic> (Family: Cupressaceae) were selected for further studies. Previous studies have shown that these plants produced various degrees of biological activities that are associated with AD [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. In addition, various parts of these plants combined in different proportions to produce ointments for inflammatory skin disorders, including AD [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. However, all of the studies are conducted on the activities of a single plant against inflammation or free radical activity. To the best of our knowledge, there is no scientific report available on the efficacy and safety of the most commonly used plant combinations.</p><p id="Par19">Based on the results of the screening assay, a 4:1:1:1:1 ratio of <italic>Cornus officinalis</italic> (fruit): <italic>Rosa multiflora</italic> (stem)<italic>, Lespedeza bicolor</italic> (aerial part), <italic>Platycladus orientalis</italic> (leaves), <italic>Castanea crenata</italic> (leaves) respectively, were selected for further studies. Additional investigation using the NO and &#x003b2;-hexosaminidase assay have demonstrated that C2RLP produced better activity than each plant extract (data not shown). Finally, a topical ointment was formulated (C2RLP) taking into account the main complaints of the disease such as pruritus, dryness, and psoriasis on the skin [<xref ref-type="bibr" rid="CR24">24</xref>]. Therefore, the study was aimed to evaluate the in vivo protective effects of topical application of herbal formulation, C2RLP, against 1-Chloro-2, 4-dinitrobenzene (DNCB) induced AD-like lesion in BALB/C mice. In addition, the effects of C2RLP on free radical scavenging activity and cellular mediators were evaluated using various in vitro methods.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Plant extraction and preparation of ointments</title><p id="Par20"><italic>Rosa multiflora</italic> (stem)<italic>, Lespedeza bicolor</italic> (aerial part), <italic>Platycladus orientalis</italic> (leaves), <italic>Castanea crenata</italic> (leaves) and <italic>Cornus officinalis</italic> (fruit) were purchased from the Gyeongbuk Forest Resource Development Institute, the Republic of Korea. The identity of the plants was confirmed by a taxonomist (Dr. Zi-Eum Im) and voucher specimens were deposited (LVPPM 2001&#x02013;2005) in our laboratory. The dried and crushed parts of each plant were boiled in 30% ethanol (100&#x02009;g/Liter). The extracts were filtered with Whatman filter paper Number 1 (GE Healthcare, UK Limited, UK), evaporated to dryness, and freeze-dried. A 5% (<italic>w</italic>/w) and 10% (w/w) ointments of C2RLP were made using petrolatum (Sigma-Aldrich) as a vehicle. For in vitro experiments on various cell lines, the extract was dissolved in the respective media used to grow the cells and then filtered using a 0.22-&#x003bc;m syringe driven filter (Merck Millipore Ltd., Carrigtwohil, Ireland).</p></sec><sec id="Sec4"><title>Experimental animals and materials</title><p id="Par21">The availability of genetically manipulated strains, ease of manipulation, and low cost of mice as compared with other species of animals makes mouse models preferable to study AD. Therefore, specific-pathogen-free male BALB/C mice of 5&#x02009;weeks old (male with an average weight of 18.5&#x02009;g) were purchased from Orient Co. Seoul, South Korea (Charles River Technology) and acclimatized for 10&#x02009;days. Mice were maintained in the animal room with 20&#x02013;25&#x02009;&#x000b0;C temperature, 55&#x02009;&#x000b1;&#x02009;10% relative humidity, and 12&#x02009;h light/dark cycle. A standard pellet diet and filtered tap water were given ad libitum. The total sample size (<italic>n</italic>&#x02009;=&#x02009;40) was calculated using the G*power program based on &#x003b1; error probability of 0.05 and power (1- &#x003b2; error probability) of 0.80. The experiment was approved by the Institutional animal care and use committee of Kyungpook National University, Republic of Korea (KNU 2016&#x02013;120). All experimental procedures were conducted according to the international guidelines for the care and use of laboratory animals [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec5"><title>In vitro experiments</title><sec id="Sec6"><title>Cell culture</title><p id="Par22">Murine macrophage RAW 264.7 cells, Rat Basophilic Leukemia cells (RBL-2H3), and human keratinocyte HaCa-T cells were obtained from the Korean Cell Line Bank, Seoul, and the Republic of Korea. RPMI medium (Roswell Park Memorial Institute) was used to maintain RAW 264.7 and RBL-2H3. The human keratinocyte HaCa-T cells were maintained in Minimum Essential Medium (MEM). Penicillin (100&#x02009;U/ml), streptomycin (100&#x02009;&#x003bc;g/ml), and fetal bovine serum (10% FBS) were added and incubated at 37&#x02009;&#x000b0;C in 5% CO<sub>2</sub> incubator. The RPMI, MEM, penicillin, streptomycin, and FBS used to supplement the medium were purchased from Sigma.</p></sec><sec id="Sec7"><title>Measurement of NO and PGE2 production</title><p id="Par23">RAW 264.7 cells (2&#x02009;&#x000d7;&#x02009;10<sup>5</sup>/ml) were cultured on 24-well plate and allowed to adhere to 80% confluence. Cells were treated with lipopolysaccharide (LPS, 0.5&#x02009;&#x003bc;g/ml) for 30&#x02009;min and incubated with C2RLP (10&#x02013;300&#x02009;&#x003bc;g/ml) for 18&#x02009;h. NO production in the supernatant was determined using a spectrophotometer at 540&#x02009;nm (VERSA max, Molecular Devices, Sunnyvale, CA, USA) and quantified from a standard curve generated using sodium nitrite (Griess Reagent System, Promega Co., Madison, WI, USA). Whereas, the level of PGE2 in the supernatant was measured using an Enzyme-linked immunosorbent assay (ELISA) kit (PGE2 ELISA kit, Cayman Chemical Co., Ann Arbor, MI, USA). In addition, the 3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was conducted to evaluate the effects of C2RLP on cellular viability following incubation of cells (2&#x02009;&#x000d7;&#x02009;10<sup>5</sup>/ml) with various concentrations of C2RLP for 24&#x02009;h.</p></sec><sec id="Sec8"><title>Evaluation of the effect of C2RLP on the expression of iNOS-mRNA</title><p id="Par24">Total RNA was extracted from RAW cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). For cDNA synthesis, 1&#x02009;&#x003bc;g of the RNA was subjected to RT reaction and amplified in triplicate using an Accu Power &#x000ae; RTPreMix and &#x000ae;PCR PreMix, respectively (Bioneer, Daejeon, Korea). The primer sequences used for amplification are summarized as follows: 5&#x02019;-GTGGGCCGCCCTAGGCACCAG-3&#x02032; (F) and 5&#x02019;-GGAGGAAGAGGATGCGGCAGT-3&#x02032;(R) for &#x003b2;-actin; and 5&#x02019;-CCCTTCCGAAGTTCTGGCAGCAGC-3&#x02032; (F) and 5&#x02019;-GGGTGTCAGAGCCTCGTGGCTTTGG-3&#x02032; (R) for iNOS. A thermal cycler system (MyCycler, Bio-Rad Laboratory, and USA) was adjusted to the following reaction conditions. Initial denaturation and enzyme activation at 95&#x02009;&#x000b0;C for 5&#x02009;min, 35&#x02009;cycle amplification at 95&#x02009;&#x000b0;C for 45&#x02009;s (denaturation), 60&#x02009;&#x000b0;C for 45&#x02009;s (annealing), and 72&#x02009;&#x000b0;C for 45&#x02009;s (extension).</p></sec><sec id="Sec9"><title>Measurement of TARC production</title><p id="Par25">The inhibitory effect of C2RLP on tumor necrosis factor-&#x003b1; and IFN-&#x003b3; (TI) (Sigma-Aldrich) induced TARC production in HaCa-T cells were evaluated in accordance with the method of Lim et al. [<xref ref-type="bibr" rid="CR26">26</xref>]. HaCa-T cells (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup>/ml) were cultured on 24-well plates and stimulated with TI. The amount of TARC produced after 24&#x02009;h following treatment with C2RLP was measured using an ELISA kit (R&#x00026;D Systems Inc., Minneapolis, MN, USA). In addition, the cytotoxicity of C2RLP on HaCa-T cells was assessed using the MTT cell proliferation assay in the presence and absence of TI (10&#x02009;ng/ml, each).</p></sec><sec id="Sec10"><title>&#x003b2;-Hexosaminidase release assay</title><p id="Par26">The effects of C2RLP on &#x003b2;-hexosaminidase release in RBL-2H3 cells was evaluated with some modifications of the method used by Kuehn et al. [<xref ref-type="bibr" rid="CR27">27</xref>]. Briefly, RBL-2H3 cells (4&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/ml) were cultured on 24-well plate and incubated at 37&#x02009;&#x000b0;C in 5% CO<sub>2</sub> for 24&#x02009;h. Following sensitization with anti-dinitrophenyl-immunoglobulin E (anti-DNP IgE) (Sigma-Aldrich) (100&#x02009;ng/ml), the cells were washed (3x) and re-suspended in Siraganian buffer. An aliquot of 100&#x02009;&#x003bc;L cells with C2RLP (10&#x02013;300&#x02009;&#x003bc;g/ml) was made into 96 well plates. Quercetin (Sigma-Aldrich) was used as a positive control. Following 30&#x02009;min of incubation at 37&#x02009;&#x000b0;C, cells were stimulated with 10&#x02009;&#x003bc;L of 100&#x02009;ng/ml of DNP-HAS (Sigma-Aldrich). The reaction was terminated by spinning the plate at 450 xg, at 4&#x02009;&#x000b0;C for 5&#x02009;min. An aliquot of 100&#x02009;&#x003bc;L 1&#x02009;&#x003bc;g/ml of N-acetyl-&#x003b2;-D-glucosamide (PNAG) (Sigma-Aldrich)) solution in citrate buffer (pH&#x02009;4.5) was made into two new 96 well plates to measure the level of secreted and total &#x003b2;-hexosaminidase. Accordingly, 50&#x02009;&#x003bc;l supernatant and 50&#x02009;&#x003bc;l cell lysates were transferred to the plates containing PNAG solution and incubated for 90&#x02009;min at 37&#x02009;&#x000b0;C. The appearance of yellow color following the addition of 50&#x02009;&#x003bc;L of 0.4&#x02009;M Glycine buffer indicated the degree of &#x003b2;-hexosaminidase activity. Finally, optical density (OD) was measured at 405&#x02009;nm and percentage &#x003b2;-hexosaminidase release was determined as follows.</p><p id="Par27">% release&#x02009;=&#x02009;100X [2(<italic>A</italic>-<italic>B</italic>))/ (1/2(<italic>C</italic>-<italic>B</italic>)&#x02009;+&#x02009;(4X (<italic>D</italic>- <italic>B</italic>)].</p><p id="Par28">Where A is the OD value of the supernatant, B is the OD value of the plate blank, C is the OD value of the total supernatant, and D is the OD value of the lysates.</p></sec><sec id="Sec11"><title>Antioxidant activity of C2RLP</title><p id="Par29">The antioxidant effect of C2RLP against DPPH free radical was conducted following a previously described method [<xref ref-type="bibr" rid="CR28">28</xref>]. The optical density was determined at 517&#x02009;nm using a multichannel spectrophotometer (VERSA max, Molecular Devices, Sunnyvale, CA, USA) and the percent inhibitory effects of the test extracts on DPPH free radicals was calculated as follows:</p><p id="Par30">
<disp-formula id="Equ2"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Inhibition}\left(\%\right)=100-\left[\frac{{\left(X\hbox{--} Y\right)}^{\ast }}{Z}100\right] $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mo>%</mml:mo><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mo>-</mml:mo><mml:mfenced close="]" open="["><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>X</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi>Y</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow></mml:mfrac><mml:mn>100</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="12906_2018_2426_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>
</p><p id="Par32">Where, X is the OD value of C2RLP with DPPH, Y is the OD value of C2RLP in ethanol, and Z is the OD value of Ethanol with DPPH.</p></sec><sec id="Sec12"><title>Compound analysis of C2RLP using liquid chromatography-mass spectrometry (LC-MS)</title><p id="Par33">LC-MS analysis of C2RLP was conducted by using an Accela UHPLC system (Thermo Fisher Scientific, CA, and USA) coupled with an LTQ-Orbitrap XL hybrid mass spectrometer (Thermo Electron, Bremen, Germany) via an ESI interface. Sample separation was carried out at room temperature using Waters BEH C18 column (2.1&#x02009;&#x000d7;&#x02009;150&#x02009;mm, 1.7&#x02009;&#x003bc;m). The mobile phase consisted of Water (A) and acetonitrile (B) with 0.1% formic acid and flow rate of 400&#x02009;&#x003bc;L/min. The elution gradient was adjusted as follows: 5% B (0&#x02009;min), 5% B (1&#x02009;min), 70% B (20&#x02009;min), 100% B (24&#x02009;min), and 100% B (27&#x02009;min). One &#x003bc;L of samples were injected and analysis was made in positive ion mode. The conditions of the ESI source were similar to a previous study [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec></sec><sec id="Sec13"><title>In vivo experiments</title><sec id="Sec14"><title>Acute oral toxicity in rats</title><p id="Par34">Acute oral toxicity of C2RLP was conducted in six 6-week old female Sprague-Dawley rats (average weight of 150&#x02009;g) purchased from Orient Co. Seoul, South Korea (Charles River Technology). The experiment was carried out according to OECD guidelines - 425. C2RLP was administered at a single oral dose of 2000&#x02009;mg/kg to three rats, while the remaining three served as untreated controls. The rats were monitored for changes in body weight, water, and food intake. Rats were also carefully inspected for abnormal signs and symptoms such as changes in the color of the skin and eyes, convulsions, diarrhea, lethargy, and coma for a total of 14&#x02009;days. Finally, rats were euthanized by carbon dioxide inhalation (flow rate adjusted to 15&#x02013;30% per minute) and pathological examination was carried out [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec15"><title>Induction of atopy and treatment of mice</title><p id="Par35">Mice were randomly allocated into five groups (<italic>N</italic>&#x02009;=&#x02009;8) as follows: Group I: treated with petrolatum (Negative control group); Group II: treated with betamethasone (Positive control group); Group III and IV: treated with 2.5 and 5% (<italic>w</italic>/w) C2RLP ointment, respectively and Group V: normal control group. The atopic lesion was induced by using 1-Chloro-2,4-dinitrobenzene (DNCB, Sigma-Aldrich) with slight modifications of previously described methods (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Immediately on the next day after shaving (day 1), mice were treated with 150&#x02009;&#x003bc;L of 1% DNCB dissolved in an acetone: olive oil mixture (3:1 vol/vol). Five days after hair removal (day 5), 150&#x02009;&#x003bc;L of 0.2% DNCB was applied to the shaved area three times a week for almost 4&#x02009;weeks (until day 33). On the 8th day after hair removal (day 8), mice were treated with C2RLP ointment daily, for 25&#x02009;days. At the end of the experiment (day 34), mice were euthanized by carbon dioxide inhalation and samples (blood and skin) were collected for chemokine analysis and histopathological examination. Blood was collected using a vacutainer tube and allowed to clot by leaving it undisturbed at room temperature for about 30&#x02009;min. The clots were removed by centrifuging at 2000x g for 10&#x02009;min in a refrigerated centrifuge. Serum was stored at -20&#x02009;&#x000b0;C until analysis. Whereas, skin specimens were fixed in 10% neutral buffered formalin.<fig id="Fig1"><label>Fig. 1</label><caption><p>Experimental schedule for induction of atopic dermatitis and treatment with C2RLP in BALB/C mice</p></caption><graphic xlink:href="12906_2018_2426_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec16"><title>Evaluation of skin lesion</title><p id="Par36">Skin lesions were recorded for each animal and dermatitis were scored once every five days, as follows [<xref ref-type="bibr" rid="CR33">33</xref>]: (1) Erythema, (2) skin dryness, (3) Edema, and (4) erosion. Scores of 0 (none), 1 (mild), 2 (moderate) and 3 (severe) were given for each lesion and the individual scores were added to determine the extent of overall dermatitis. A researcher who was unaware of the treatment and control groups conducted the evaluation of dermatitis score.</p></sec><sec id="Sec17"><title>Histopathological investigation</title><p id="Par37">Paraffin-embedded specimens were sectioned to 5&#x02009;&#x003bc;m thicknesses and subjected to the automated tissue processor. Hematoxylin-Eosin (HE) and Toluidine blue (TB) stained skins sections were examined to determine the degree of epidermal hyperplasia, inflammatory and mast cell infiltration. A pathologist who was unaware of the treatment and control groups performed a microscopic evaluation of skin lesions.</p></sec><sec id="Sec18"><title>Th2 and Th1 cytokines</title><p id="Par38">Serum samples were harvested from blood samples collected at the end of the experiment and the levels of IL-2, IL-4, IL-5, IL-6 IL-13, and IFN-&#x003d2; were analyzed using ELISA kits following the manufacturers&#x02019; instructions.</p></sec></sec><sec id="Sec19"><title>Statistical analysis</title><p id="Par39">Data are presented as means &#x000b1; standard deviation (SD). One-way analysis of variance (ANOVA) was conducted by using Prism (GraphPad Software Inc., USA) followed by Tukey&#x02019;s honestly significant difference (HSD) test. Differences with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec20"><title>Results</title><sec id="Sec21"><title>Effects of C2RLP on nitrite and PGE2 production in RAW 264.7 cells</title><p id="Par40">MTT assay was used to evaluate the effect of C2RLP on the viability of RAW 264.7 cells with an initial concentration of 1&#x02009;mg/ml. The result demonstrated that &#x0003e;&#x02009;85% of the cells were alive at the tested concentrations (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). Cells were stimulated with LPS (0.5&#x02009;&#x003bc;g/ml) prior to treatment with various concentrations of C2RLP, and the levels of NO and PGE2 production were measured after 24&#x02009;h. LPS stimulated cells produced a higher amount of nitrite (40.5&#x02009;&#x000b1;&#x02009;0.7&#x02009;&#x003bc;M) (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) with respect to the non-stimulated cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b<bold>)</bold>. However, treatment with 100 and 300&#x02009;&#x003bc;g/ml of C2RLP significantly reduced (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) the LPS-induced nitrite production. In accordance with the findings in the NO assay, a significant suppression of iNOS gene expression was observed following treatment with C2RLP (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). On the other hand, the level of PGE2 in the cell culture supernatant of LPS-stimulated cells (15.1&#x02009;&#x000b1;&#x02009;0.4&#x02009;ng/ml) reduced significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) only in 300&#x02009;&#x003bc;g/ml C2RLP treated cells with a mean concentration of 10.5&#x02009;&#x000b1;&#x02009;0.2&#x02009;ng/ml (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d<bold>)</bold>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of C2RLP on viability (<bold>a</bold>), NO production (<bold>b</bold>), iNOS-mRNA expression (<bold>c</bold>), and PGE2 production (<bold>d</bold>) of LPS stimulated RAW 264.7 cells. The data shown represent the means of three independent experiments and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec22"><title>C2RLP treatment reduced TARC production in HaCa-T cells</title><p id="Par41">HaCa-T cells were stimulated with TI and treated with various concentrations of C2RLP for 24&#x02009;h. The amount of TARC production in cells stimulated with TI elevated almost 7-fold with respect to the non-stimulated cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a). The TI induced TARC production was reduced by 49.78 and 22.92% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) following treatment with 300 and 100&#x02009;&#x003bc;g/ml of C2RLP, respectively. In addition, the cytotoxic effect of the test concentrations of C2RLP in HaCa-T cells was assessed prior to determining its effect on TARC production. The results have demonstrated that the test concentrations did not interfere with the viability of HaCa-T cells, both in the presence and absence of TI (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b).<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of C2RLP on TARC production (<bold>a</bold>) and viability (<bold>b</bold>) in HaCa-T cells. The data shown represent the means of three independent experiments and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec23"><title>Effect of C2RLP on &#x003b2;-hexosaminidase release in RBL-2H3 cells</title><p id="Par42">The release of &#x003b2;-hexosaminidase from IgE-DNP antibody sensitized RBL-2H3 cells was evaluated to determine the effect of C2RLP on mast cell degranulation. C2RLP significantly reduced (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) &#x003b2;-hexosaminidase release at concentrations of 100 and 300&#x02009;&#x003bc;g/ml (IC<sub>50</sub>&#x02009;=&#x02009;179.5&#x02009;&#x003bc;g/ml) with a percentage inhibition of 43.1&#x02009;&#x000b1;&#x02009;1.9 and 57.5&#x02009;&#x000b1;&#x02009;3.8, respectively. In addition, MTT assay demonstrated that C2RLP was non-toxic in both IgE-DNP stimulated and non-stimulated RBL-2H3 cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref> a,b and c).<fig id="Fig4"><label>Fig. 4</label><caption><p>The effects of C2RLP on &#x003b2;-hexosaminidase release (<bold>a</bold>) and viability (<bold>b</bold>) in IgE-DNP antibody sensitized RBL-2H3 cells. The &#x003b2;-hexosaminidase inhibitory activity (IC<sub>50</sub> value) of C2RLP was also determined (<bold>c</bold>). The data shown represent the means of three independent experiments and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec24"><title>Antioxidant activity of C2RLPC</title><p id="Par43">The DPPH free radical scavenging assay was conducted to evaluate the scavenging capacity of C2RLP at various concentrations. The result demonstrated a concentration-dependent inhibitory activity of free radicals with an IC<sub>50</sub> value of 147.5&#x02009;&#x003bc;g/ml (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>DPPH free radical scavenging activity of C2RLP (IC<sub>50</sub>) following incubation of the C2RLP and DPPH solution at 37&#x02009;&#x000b0;C for 30&#x02009;min</p></caption><graphic xlink:href="12906_2018_2426_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec25"><title>LC-MS analysis of C2RLP</title><p id="Par44">The main constituents of C2RLP identified by LC-MS are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. C2RLP possess various compounds that belong mainly to the flavonoids and phenols. Loganin, Ellagic acid, and Kaempferol 3-glucoside were the main compounds identified in C2RLP with retention times of 5.7, 6.4, and 7.5&#x02009;min, respectively.<table-wrap id="Tab1"><label>Table 1</label><caption><p>LC-MS analysis of compounds of C2RLP</p></caption><table frame="hsides" rules="groups"><thead><tr><th>RT (min)</th><th>m/z</th><th>&#x025b3;ppm</th><th>MS/MS</th><th>Formula</th><th>Name of compound</th></tr></thead><tbody><tr><td>3.4</td><td>347.1 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;0.98</td><td>183</td><td>C14H19O10</td><td>Glucopyranosyl methyl gallate</td></tr><tr><td>5.7</td><td>391.2 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;0.52</td><td>246</td><td>C17H27O10</td><td>Loganin</td></tr><tr><td>6.3</td><td>617.1 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;0.94</td><td>303, 315, 599</td><td>C28H25O16</td><td>Quercetin 3-b-galactoside-2&#x02019;-O-gallate</td></tr><tr><td>6.4</td><td>303 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>0.65</td><td/><td>C14H7O8</td><td>Ellagic acid</td></tr><tr><td>6.7</td><td>479.1 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;1.51</td><td>303</td><td>C21H19O13</td><td>Quercetin-3-Glucoronide</td></tr><tr><td>7.5</td><td>449.1 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;0.93</td><td/><td>C21H21O11</td><td>Kaempferol 3-glucoside</td></tr><tr><td>8.1</td><td>543.2 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>0.18</td><td>381</td><td>C24H31O14</td><td>Cornuside</td></tr><tr><td>8.2</td><td>433 ([M-H]<sup>&#x02212;</sup>)</td><td/><td>271</td><td>C21H21O10</td><td>Naringenin7-O-&#x003b2;-D-glucoside</td></tr><tr><td>9.5</td><td>303.1 ([M&#x02009;+&#x02009;H]<sup>+</sup>)</td><td>&#x02212;0.65</td><td>151, 179, 273</td><td>C15H11O7</td><td>Quercetin</td></tr></tbody></table><table-wrap-foot><p>RT, retention time; ([M&#x02009;+&#x02009;H]<sup>+</sup>)/ ([M-H]<sup>&#x02212;</sup>) base or molecular ions at the positive and negative mode, respectively</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec26"><title>Acute oral toxicity</title><p id="Par45">Oral administration of C2RLP extract was safe up to 2000&#x02009;mg/kg body weight. None of the rats showed any signs of toxicity such as weight loss, restlessness, ruffled hair, lacrimation, diarrhea, and convulsion.</p></sec><sec id="Sec27"><title>Effect of C2RLP ointment on AD-like skin lesions in mice</title><p id="Par46">Cutaneous findings related to atopic dermatitis such as mild to moderate erythema, skin dryness, edema, and erosion were evident following application of DNCB for almost 2&#x02009;weeks (with an average dermatitis score of 6.8) in the petrolatum treated control mice. Topical application of C2RLP and betamethasone significantly suppressed (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) the cutaneous symptoms as of the 5th and 10th day of treatment, respectively. However, a slight degree of erythema and alopecia were evident in the 2.5% C2RLP treated group. At the end of treatment, the average dermatitis score of the 2.5, 5% C2RLP and betamethasone treated mice were 3.4&#x02009;&#x000b1;&#x02009;0.5, 2.6&#x02009;&#x000b1;&#x02009;0.5 and 2.1&#x02009;&#x000b1;&#x02009;0.4, respectively (Fig. <xref rid="Fig6" ref-type="fig">6</xref> a, b, c, d, e, f). These findings were 2&#x02013;3 folds lower than the dermatitis score recorded for the petrolatum treated control mice. Therefore, C2RLP produced a concentration-dependent attenuation of DNCB induced AD-like skin lesions in mice.<fig id="Fig6"><label>Fig. 6</label><caption><p>Representative photographs of mouse dorsal skin showing various degrees of alopecia, skin dryness, and erythematous lesions after 2&#x02009;days of treatment indicated no difference between treatment and control groups (A). Photographs of mice treated with petrolatum (<bold>a</bold>), 2.5% C2RLP (<bold>b</bold>), 5% C2RLP (<bold>c</bold>), and Betamethasone (<bold>d</bold>) indicated treatment with the test substance enhanced the recovery of mice from AD-like lesions compared with petrolatum. Dermatitis score at the end of treatment (day 33) showing a significant difference with respect to DNCB treated control mice (<bold>e</bold>). The data shown in Fig. E represent mean&#x02009;+&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;8) and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec28"><title>Effect of C2RLP on DNCB induced histopathological changes of mouse skin</title><p id="Par47">HE-stained skin sections exhibited marked epidermal hyperplasia and inflammatory cell infiltration into the dermal skin layer of the petrolatum treated mice (Fig. <xref rid="Fig7" ref-type="fig">7</xref>a<bold>)</bold>. The epidermis of the petrolatum treated control mice were 4.8 fold thicker than the normal control mice. However, treatment with C2RLP and betamethasone exhibited 18.9&#x02013;54.6% reduction in epidermal hyperplasia and suppressed cellular infiltration compared with the petrolatum treated control. Moreover, the number of mast cells in the dermal layer of the skin was markedly reduced in the C2RLP treated mice with respect to the petrolatum treated mice (Fig. <xref rid="Fig7" ref-type="fig">7</xref> b,c,d).<fig id="Fig7"><label>Fig. 7</label><caption><p>HE (<bold>a</bold>) and TB (<bold>b</bold>) stained skin sections (200x magnification) indicating the effect of C2RLP treatment on the degree of inflammatory cell infiltration and epidermal hyperplasia. Epidermal thickness (<bold>c</bold>) and, the number of mast cells (<bold>d</bold>) was determined in the HE and TB-stained sections, respectively (<italic>n</italic>&#x02009;=&#x02009;6). The data shown represent the means of three independent experiments and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec29"><title>Effects of C2RLP on serum levels of cytokines</title><p id="Par48">The serum levels of IL-4 in the 2.5 and 5% C2RLP ointment treated groups were 41.7&#x02009;&#x000b1;&#x02009;2.5 and 37.6&#x02009;&#x000b1;&#x02009;3.9&#x02009;pg/ml, respectively. C2RLP reduced the serum levels of IL-4 in a dose-dependent manner with respect to DNCB treated control group. However, treatment did not produce a significant change (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) in the level of IFN-&#x003d2; among treatment groups (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref> a and b). In our study, the levels of IL-2, IL-5, IL-6 IL-10, and IL-13 were not detectable in the serum of Balb/C mice (data not shown).<fig id="Fig8"><label>Fig. 8</label><caption><p>Effects of topical C2RLP treatment on serum levels of IL-4 (<bold>a</bold>) and IFN-&#x003b3; (<bold>b</bold>) of DNCB treated mice. The data shown represent the mean&#x02009;&#x000b1;&#x02009;SD (n&#x02009;=&#x02009;8) and bars with different letters indicate significant difference (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="12906_2018_2426_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec30"><title>Discussion</title><p id="Par49">AD results in various histopathological and pathophysiological changes in mice, which are related to alterations in the levels of proinflammatory cytokines, IgE, and histamine [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. These changes resulted in epidermal hyperplasia, inflammatory cell infiltration, erythema, alopecia, skin dryness and hyperkeratosis [<xref ref-type="bibr" rid="CR35">35</xref>] which were clearly observed in petrolatum treated control mice shown in Figs. <xref rid="Fig6" ref-type="fig">6</xref> and <xref rid="Fig7" ref-type="fig">7</xref>. The binding of antigen activates infiltrated cells to secrete chemical mediators such as histamine, proteases, cytokines, and chemokines that are essential in the progression of dermatitis [<xref ref-type="bibr" rid="CR36">36</xref>]. Our study showed that C2RLP treatment suppressed the DNCB induced AD-like lesions and histopathological changes, including epidermal hyperplasia and inflammatory cell infiltration.</p><p id="Par50">The Th1/Th2 cytokine imbalance is vital in the progression of atopic dermatitis, with increased production of IgE and mast cell activation in Th2-dominant AD [<xref ref-type="bibr" rid="CR37">37</xref>]. Studies have shown that compounds isolated from plants modulate the Th1 and/or Th2 cell response and prevents the development of AD in mice [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. More precisely, Th2 cytokines such as IL-4, IL-5, IL-13, and IL-4 mediated increment of serum IgE and mast cells were reported in mice with symptoms of AD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In this study, C2RLP significantly reduced the serum levels of IL-4 with respect to petrolatum. IL-4 is known to activate mast cells by inducing isotype switching to IgE synthesis by B cells. The binding of IgE with allergens activates the immune system and induces degranulation [<xref ref-type="bibr" rid="CR40">40</xref>]. In contrast, C2RLP did not affect the DNCB induced production of IFN-&#x003b3; which are strong inhibitors of IgE synthesis and Th2 cell proliferation [<xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, down-regulation of Th2 immunity could be considered as a possible mechanism for the mechanism of C2RLP against AD.</p><p id="Par51">AD is commonly associated with marked infiltration of the skin by mast cells, eosinophils and macrophages [<xref ref-type="bibr" rid="CR2">2</xref>]. Macrophages are known to release proinflammatory mediators such as NO and PGE<sub>2</sub>, which aggravate the inflammatory responses [<xref ref-type="bibr" rid="CR41">41</xref>]. Regulation NO production and iNOS expression might be essential because it is known to affect the pathogenesis of several inflammatory diseases, including AD [<xref ref-type="bibr" rid="CR42">42</xref>]. In the current study, C2RLP inhibited the LPS induced production of NO and PGE<sub>2</sub> in RAW 264.7 macrophage cells. In addition, C2RLP produced a dose-dependent attenuation of iNOs-mRNA expression.</p><p id="Par52">Chemokines produced by keratinocytes can cause an imbalance in Th1/Th2 cytokines and contributes to the development of atopic lesions [<xref ref-type="bibr" rid="CR4">4</xref>]. The expression of TARC by keratinocytes in AD patients and in mice with atopic lesions was confirmed in previous studies. TARC is known to attract Th2 cells and aggravates the pathological changes related to AD [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In this study, the production of TARC by TI-sensitized HaCa-T cells was reduced following treatment with 300 and 100&#x02009;&#x003bc;g/ml of C2RLP consolidating the Th2 cell suppressing effects of C2RLP.</p><p id="Par53">Degranulation of activated mast cells and release of mediators are suggested in allergic reactions associated with AD. Mast cell degranulation can be determined by measuring the amount of &#x003b2;-hexosaminidase released from various cell lines including RBL-2H3 [<xref ref-type="bibr" rid="CR45">45</xref>]. Inflammatory mediators are released from degranulated mast cells following an Fc epsilon RI (Fc&#x003b5;RI) receptor activation, which is a high-affinity IgE receptor [<xref ref-type="bibr" rid="CR46">46</xref>]. In our study, C2RLP exhibited a concentration-dependent inhibition of &#x003b2;-hexosaminidase release from RBL-2H3 cells (IC<sub>50</sub>&#x02009;=&#x02009;179.5&#x02009;&#x003bc;g/ml) with significant inhibitory activity at 300&#x02009;&#x003bc;g/ ml. Direct inhibition of Fc&#x003b5;RI cascade could be one of the mechanisms of the anti-atopic activity of C2RLP.</p><p id="Par54">Oxidative stress in AD is associated with an increase in lipid peroxidation and reduction in the levels of antioxidants. It promotes tissue inflammation through upregulation of genes that code for pro-inflammatory cytokines and subsequent release of free radicals [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Oxidative stress can also alter the integrity of epidermal keratinocytes by damaging DNA and cellular enzymes [<xref ref-type="bibr" rid="CR49">49</xref>]. Previous studies have confirmed higher levels of lipid peroxidation and lower levels of antioxidants in patients with inflammatory skin conditions that resembles AD such as eczema [<xref ref-type="bibr" rid="CR50">50</xref>] and alopecia areata [<xref ref-type="bibr" rid="CR51">51</xref>]. Therefore, the antioxidant activity of C2RLP could contribute to the reduction in reactive oxygen species and alleviate the oxidative stress associated with AD.</p><p id="Par55">Chemical compounds are implicated directly or indirectly in the biological effects of most plant extracts. The study revealed the presence of various compounds in C2RLP, mainly Loganin, Ellagic acid, and Kaempferol 3-glucoside (Table <xref rid="Tab1" ref-type="table">1</xref>). Previous studies indicated that suppression of NF-&#x003ba;B and MAP- kinases (mitogen-activated protein kinases) are critical to inhibit the secretion of pro-inflammatory cytokines and reduce the number of mast cells, which are involved in the inflammatory response [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Among the major metabolites, loganin is reported to inhibit NF-&#x003ba;B activation and MAP kinase [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. The polyphenolic compound, ellagic acid, is suggested to have a diverse biological activity, including antibacterial, antioxidant, anti-inflammatory and anti-carcinogenic actions [<xref ref-type="bibr" rid="CR56">56</xref>]. Most importantly, Ellagic acid has been shown to inhibit activation of MAP kinases [<xref ref-type="bibr" rid="CR57">57</xref>] and repress NF-&#x003ba;B through down-regulation of the secretion of various inflammatory mediators during AD [<xref ref-type="bibr" rid="CR58">58</xref>]. Kaempferol-3-O-glucoside and its derivatives were also reported to produce an anti-inflammatory effect through inhibition of the activation of cyclooxygenase (COX-2) and iNOS [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. In addition to the three major compounds, the antioxidant and anti-inflammatory effects of cornuside [<xref ref-type="bibr" rid="CR61">61</xref>], naringenin7-O-&#x003b2;-D-glucoside [<xref ref-type="bibr" rid="CR62">62</xref>], and quercetin [63] could also contribute to the protective effect of C2RLP in the development of AD. Therefore, suppression of AD-like lesions in C2RLP treated mice might be due to the synergistic action of these compounds.</p></sec><sec id="Sec31"><title>Conclusions</title><p id="Par56">The study results confirmed the absence of in vitro and in vivo toxic effects of C2RLP. C2RLP attenuates the symptoms of atopic dermatitis in mice by modifying local and systemic inflammation. It produces a marked reduction in dermatitis score and inflammatory cell infiltration; and decreased the production of IL-4, NO, PGE2, and TARC. C2RLP also suppressed &#x003b2;-hexosaminidase release, which is the hallmark of allergic reactions and mast cell degranulation. Therefore, the findings of this study suggest that topical application of C2RLP might be effective in preventing the development of AD. However, detailed studies on the molecular mechanism (s) of C2RLP are needed.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p id="Par5">Atopic dermatitis</p></def></def-item><def-item><term>DNCB</term><def><p id="Par6">1-Chloro-2, 4-dinitrobenzene</p></def></def-item><def-item><term>HE</term><def><p id="Par7">Hematoxylin-Eosin</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par8">Interferon- &#x003b3;</p></def></def-item><def-item><term>IgE</term><def><p id="Par9">Immunoglobulin-E</p></def></def-item><def-item><term>LC-MS</term><def><p id="Par10">Liquid chromatography mass-spectrometry</p></def></def-item><def-item><term>NO</term><def><p id="Par11">Nitrite</p></def></def-item><def-item><term>PGE2</term><def><p id="Par12">Prostaglandin E2</p></def></def-item><def-item><term>TARC</term><def><p id="Par13">Thymus and activation-regulated chemokine</p></def></def-item><def-item><term>TB</term><def><p id="Par14">Toluidine blue</p></def></def-item><def-item><term>Th2</term><def><p id="Par15">T-helper 2</p></def></def-item></def-list></glossary><ack><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par57">This study was supported by Forest Resources Development Institute of Gyeongsangbuk-do, and in part by the Cooperative Research Program for Agriculture, Science and Technology Development, Rural Development Administration (PJ01128901), Korea forest service. The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.</p></sec><sec id="FPar2" sec-type="data-availability"><title>Availability of data and materials</title><p id="Par58">The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contribution</title><p>AFM designed and conducted the study; analyzed the data, and prepared the manuscript. SJL, NHP, JYK, and ZEI prepared the extracts and revised the manuscript. JWS and SCP designed the study and revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>Experimental procedures were carried out according to the international guidelines for the care and use of laboratory animals. The experiment was approved by the Institutional animal care and use committee, Kyungpook National University, Republic of Korea (Approval number: KNU 2016&#x02013;120).</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudikoff</surname><given-names>D</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name></person-group><article-title>Atopic dermatitis</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1715</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)12082-7</pub-id><pub-id pub-id-type="pmid">9734903</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Leung DYM, Bieber T. Atopic dermatitis. Lancet. 2003:151&#x02013;60.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>DeLeo</surname><given-names>V</given-names></name><name><surname>Soter</surname><given-names>NA</given-names></name></person-group><article-title>Allergic and immunologic skin disorders</article-title><source>JAMA</source><year>1997</year><volume>278</volume><issue>22</issue><fpage>1914</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550220120016</pub-id><pub-id pub-id-type="pmid">9396653</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Ham</surname><given-names>IH</given-names></name><name><surname>Choi</surname><given-names>HY</given-names></name></person-group><article-title>Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice</article-title><source>J Ethnopharmacol</source><year>2011</year><volume>138</volume><issue>2</issue><fpage>398</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.09.028</pub-id><pub-id pub-id-type="pmid">21963561</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewe</surname><given-names>M</given-names></name><name><surname>Gyufko</surname><given-names>K</given-names></name><name><surname>Sch&#x000f6;pf</surname><given-names>E</given-names></name><name><surname>Krutmann</surname><given-names>J</given-names></name></person-group><article-title>Lesional expression of interferon-gamma in atopic eczema</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>25</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)90879-6</pub-id><pub-id pub-id-type="pmid">7905045</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thepen</surname><given-names>T</given-names></name><name><surname>Langeveld-Wildschut</surname><given-names>EG</given-names></name><name><surname>Bihari</surname><given-names>IC</given-names></name><name><surname>Van Wichen</surname><given-names>DF</given-names></name><name><surname>Van Reijsen</surname><given-names>FC</given-names></name><name><surname>Mudde</surname><given-names>GC</given-names></name><etal/></person-group><article-title>Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial T(H2) response to a T(H1) response in situ: An immunocytochemical study</article-title><source>J Allergy Clin Immunol</source><year>1996</year><volume>97</volume><issue>3</issue><fpage>828</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(96)80161-8</pub-id><pub-id pub-id-type="pmid">8613640</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname><given-names>C</given-names></name><name><surname>Bang</surname><given-names>K</given-names></name><name><surname>Gesser</surname><given-names>B</given-names></name><name><surname>Yoneyama</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>CG</given-names></name></person-group><article-title>A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin</article-title><source>J Invest Dermatol</source><year>2000</year><volume>115</volume><issue>4</issue><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00115.x</pub-id><pub-id pub-id-type="pmid">10998136</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiohara</surname><given-names>T</given-names></name><name><surname>Hayakawa</surname><given-names>J</given-names></name><name><surname>Mizukawa</surname><given-names>Y</given-names></name></person-group><article-title>Animal models for atopic dermatitis: are they relevant to human disease? Vol. 36</article-title><source>J Dermatol Sci</source><year>2004</year><volume>36</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2004.02.013</pub-id><pub-id pub-id-type="pmid">15488700</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuksel</surname><given-names>H</given-names></name><name><surname>Kirmaz</surname><given-names>C</given-names></name><name><surname>Yilmaz</surname><given-names>O</given-names></name><name><surname>Pinar</surname><given-names>E</given-names></name></person-group><article-title>Nasal mucosal expression of nitric oxide synthases in patients with allergic rhinitis and its relation to asthma</article-title><source>Ann Allergy Asthma Immunol</source><year>2007</year><volume>100</volume><issue>1</issue><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)60398-5</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollenberg</surname><given-names>A</given-names></name><name><surname>Reitamo</surname><given-names>S</given-names></name><name><surname>Atzori</surname><given-names>F</given-names></name><name><surname>Lahfa</surname><given-names>M</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Healy</surname><given-names>E</given-names></name><etal/></person-group><article-title>Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment</article-title><source>Allergy Eur J Allergy Clin Immunol</source><year>2008</year><volume>63</volume><issue>6</issue><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2007.01406.x-i1</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DYM</given-names></name></person-group><article-title>Atopic dermatitis: new insights and opportunities for therapeutic intervention</article-title><source>J Allergy Clin Immunol</source><year>2000</year><volume>105</volume><issue>5</issue><fpage>860</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1067/mai.2000.106484</pub-id><pub-id pub-id-type="pmid">10808164</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>CD</given-names></name></person-group><article-title>Complementary and alternative medicine in Korea: current status and future prospects</article-title><source>J Altern Complement Med</source><year>2001</year><volume>7</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1089/107555301753393788</pub-id><pub-id pub-id-type="pmid">11246934</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S-Y</given-names></name><name><surname>Pei</surname><given-names>Y-H</given-names></name><name><surname>Zeng</surname><given-names>H-W</given-names></name><name><surname>Zhang</surname><given-names>S-D</given-names></name><name><surname>Li</surname><given-names>Y-L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Compounds from Platycladus orientalis and their inhibitory effects on nitric oxide and TNF-alpha production</article-title><source>Planta Med</source><year>2011</year><volume>77</volume><issue>14</issue><fpage>1623</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1055/s-0030-1270905</pub-id><pub-id pub-id-type="pmid">21412696</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>K-A</given-names></name><name><surname>Hwang</surname><given-names>Y-J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Antioxidant activities and oxidative stress inhibitory effects of ethanol extracts from Cornus officinalis on raw 264</article-title><source>7 cells BMC Complement Altern Med</source><year>2016</year><volume>16</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26729470</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>CS</given-names></name><name><surname>Choi</surname><given-names>HI</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Antioxidant activity of Rosa multiflora Thunb. Flower extract and suppressive activity on proinflammatory mediator production in lipopolysaccharide-stimulated RAW 264. 7 macrophages</article-title><source>FFHD</source><year>2016</year><volume>6</volume><issue>5</issue><fpage>265</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.31989/ffhd.v6i5.248</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Hossaine</surname><given-names>MDA</given-names></name></person-group><article-title>Park SC. A potential anti-inflammation activity and depigmentation effect of Lespedeza bicolor extract and its fractions</article-title><source>Saudi J Biol Sci</source><year>2016</year><volume>23</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2015.01.016</pub-id><pub-id pub-id-type="pmid">26858533</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname><given-names>UY</given-names></name><name><surname>Shon</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>GN</given-names></name><name><surname>Katagiri</surname><given-names>R</given-names></name><name><surname>Harata</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Antioxidant and anti-adipogenic activities of chestnut (Castanea crenata) byproducts</article-title><source>Food Sci Biotechnol</source><year>2016</year><volume>25</volume><issue>4</issue><fpage>1169</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1007/s10068-016-0186-4</pub-id><pub-id pub-id-type="pmid">30263390</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyase</surname><given-names>T</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Nakai</surname><given-names>H</given-names></name><name><surname>Muraoka</surname><given-names>M</given-names></name><name><surname>Nakazawa</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antioxidants from Lespedeza homoloba. (I)</article-title><source>Phytochemistry</source><year>1999</year><volume>52</volume><issue>2</issue><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(99)00195-8</pub-id><pub-id pub-id-type="pmid">10513403</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>N</given-names></name></person-group><article-title>Study on the anti-inflammatory effect of <italic>Biota orientalis</italic></article-title><source>J Chin Pharm Univ</source><year>2001</year><volume>32</volume><fpage>224</fpage><lpage>226</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapkota</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>S-E</given-names></name><name><surname>Kim</surname><given-names>J-E</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>H-S</given-names></name><name><surname>Chun</surname><given-names>H-S</given-names></name><etal/></person-group><article-title>Antioxidant and anti-melanogenic properties of chestnut flower extract</article-title><source>Biosci Biotechnol Biochem</source><year>2010</year><volume>74</volume><issue>8</issue><fpage>1527</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1271/bbb.100058</pub-id><pub-id pub-id-type="pmid">20699587</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>MJ</given-names></name></person-group><article-title>Analysis and recordings of orally transmitted knowledge about medicinal plants in the southern mountainous region of Korea</article-title><source>J Ethnopharmacol</source><year>2011</year><volume>134</volume><fpage>676</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.01.024</pub-id><pub-id pub-id-type="pmid">21256949</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>B</given-names></name></person-group><article-title>Anti-oxidant and anti-inflammatory effects of Rosa multiflora root</article-title><source>J Life Sci</source><year>2011</year><volume>21</volume><issue>8</issue><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.5352/JLS.2011.21.8.1120</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhavan</surname><given-names>N</given-names></name><name><surname>Feresin</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Pourafshar</surname><given-names>S</given-names></name><name><surname>Elam</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Cornus officinalis modulates the production of proinflammatory molecules in lipopolysaccharide-activated RAW264</article-title><source>7 macrophages FASEB J</source><year>2015</year><volume>29</volume><fpage>922</fpage><lpage>930</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Ant&#x000f3;n Mart&#x000ed;nez</surname><given-names>MC</given-names></name><name><surname>Leis-Dosil</surname><given-names>V</given-names></name><name><surname>Alfageme-Rold&#x000e1;n</surname><given-names>F</given-names></name><name><surname>Paravisini</surname><given-names>A</given-names></name><name><surname>S&#x000e1;nchez-Ram&#x000f3;n</surname><given-names>S</given-names></name><name><surname>Su&#x000e1;rez Fern&#x000e1;ndez</surname><given-names>R</given-names></name></person-group><article-title>Omalizumab for the treatment of atopic dermatitis</article-title><source>Actas Dermosifiliogr</source><year>2012</year><volume>103</volume><issue>7</issue><fpage>624</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.ad.2011.07.013</pub-id><pub-id pub-id-type="pmid">22056257</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Louhimies S. Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. In: ATLA Alternatives to Laboratory Animals. European Community (EU) guidelines. 2002. p. 217&#x02013;9.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>H-S</given-names></name><name><surname>Ha</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>M-Y</given-names></name><name><surname>Shin</surname><given-names>H-K</given-names></name></person-group><article-title>Morus alba L. suppresses the development of atopic dermatitis induced by the house dust mite in NC/Nga mice</article-title><source>BMC Complement Altern Med</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>139</fpage><pub-id pub-id-type="doi">10.1186/1472-6882-14-139</pub-id><pub-id pub-id-type="pmid">24755250</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Radinger</surname><given-names>M</given-names></name><name><surname>Gilfillan</surname><given-names>AM</given-names></name></person-group><article-title>Measuring mast cell mediator release</article-title><source>Curr Protoc Immunol</source><year>2010</year><volume>9</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>ZQ</given-names></name><name><surname>Hwang</surname><given-names>MH</given-names></name><name><surname>Rhee</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><etal/></person-group><article-title>The in vitro anti-platelet, antioxidant and cellular immunity activity of Phellinus gilvus fractional extracts</article-title><source>World J Microbiol Biotechnol</source><year>2008</year><volume>24</volume><issue>2</issue><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/s11274-007-9454-z</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Rapid separation and characterization of diterpenoid alkaloids in processed roots of Aconitum carmichaeli using ultra high-performance liquid chromatography coupled with hybrid linear ion trap-Orbitrap tandem mass spectrometry</article-title><source>J Sep Sci</source><year>2014</year><volume>37</volume><issue>20</issue><fpage>2864</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1002/jssc.201400365</pub-id><pub-id pub-id-type="pmid">25124198</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>OECD/OCDE</collab></person-group><article-title>Acute Oral toxicity &#x02013; up-and-Down-procedure (UDP)</article-title><source>Oecd Guidel Test Chem</source><year>2008</year><volume>425</volume><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>YY</given-names></name><name><surname>Yoon</surname><given-names>T</given-names></name><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Jeong</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name></person-group><article-title>Inhibitory effects of Cinnamomum cassia extract on atopic dermatitis-like skin lesions induced by mite antigen in NC/Nga mice</article-title><source>J Ethnopharmacol</source><year>2011</year><volume>133</volume><issue>2</issue><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.10.043</pub-id><pub-id pub-id-type="pmid">21035532</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">YYoon H-J, Jang M-S, Kim H-W, Song D-U, Nam K-I, Bae C-S, et al. Protective effect of diet supplemented with rice prolamin extract against DNCB-induced atopic dermatitis in BALB/c mice. BMC Complement Altern Med. 2015;15:353.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pokharel</surname><given-names>YR</given-names></name><name><surname>Lim</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name></person-group><article-title>Inhibition of dermatitis development by sopungsan in NC/NGA mice</article-title><source>Toxicol Res</source><year>2008</year><volume>24</volume><issue>1</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5487/TR.2008.24.1.017</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Shintani</surname><given-names>T</given-names></name><name><surname>Yamatodani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of a traditional herbal medicine, hochu-ekki-to in the long-term management of Kikyo (delicate constitution) patients with atopic dermatitis: a 6-month, multicenter, double-blind, randomized, placebo-controlled study</article-title><source>Evidence-based Complement Altern Med</source><year>2010</year><volume>7</volume><issue>3</issue><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1093/ecam/nen003</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Stone KD, Prussin C, Metcalfe DD. NIH Public Access 2011;125:1&#x02013;16.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DB</given-names></name></person-group><article-title>Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy?</article-title><source>Curr Opin Immunol</source><year>2002</year><volume>14</volume><fpage>644</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(02)00388-6</pub-id><pub-id pub-id-type="pmid">12183167</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiu</surname><given-names>KG</given-names></name><name><surname>Fuseda</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Inagaki</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name></person-group><article-title>Kampo medicines for mite antigen-induced allergic dermatitis in NC/Nga mice</article-title><source>Evidence-based Complement Altern Med.</source><year>2005</year><volume>2</volume><issue>2</issue><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh077</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohmura</surname><given-names>T</given-names></name><name><surname>Tsunenari</surname><given-names>I</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>Y</given-names></name><name><surname>Konomi</surname><given-names>A</given-names></name><name><surname>Nanri</surname><given-names>H</given-names></name><etal/></person-group><article-title>Role of substance P in an NC/Nga mouse model of atopic dermatitis-like disease</article-title><source>Int Arch Allergy Immunol</source><year>2004</year><volume>133</volume><issue>4</issue><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1159/000077359</pub-id><pub-id pub-id-type="pmid">15031613</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>SK</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Pyo</surname><given-names>MY</given-names></name></person-group><article-title>Inonotus obliquus extracts suppress antigen-specific IgE production through the modulation of Th1/Th2 cytokines in ovalbumin-sensitized mice</article-title><source>J Ethnopharmacol</source><year>2011</year><volume>137</volume><issue>3</issue><fpage>1077</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.07.024</pub-id><pub-id pub-id-type="pmid">21820502</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval-L&#x000f3;pez</surname><given-names>G</given-names></name><name><surname>Teran</surname><given-names>LM</given-names></name></person-group><article-title>TARC: novel mediator of allergic inflammation</article-title><source>Clin Exp Allergy</source><year>2001</year><volume>31</volume><issue>12</issue><fpage>1809</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2001.01268.x</pub-id><pub-id pub-id-type="pmid">11737030</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>MM</given-names></name><name><surname>Huang</surname><given-names>HI</given-names></name><name><surname>Fenton</surname><given-names>MR</given-names></name><name><surname>Fong</surname><given-names>D</given-names></name></person-group><article-title>In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties</article-title><source>Biochem Pharmacol</source><year>1998</year><volume>55</volume><issue>98</issue><fpage>1955</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(98)00114-2</pub-id><pub-id pub-id-type="pmid">9714315</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname><given-names>C</given-names></name><name><surname>Yoneyama</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name></person-group><article-title>The NC / Nga mouse : a model for atopic dermatitis</article-title><source>Mol Med Today</source><year>2000</year><volume>6</volume><fpage>209</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S1357-4310(00)01683-X</pub-id><pub-id pub-id-type="pmid">10782068</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Takehara</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name></person-group><article-title>Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis</article-title><source>J Dermatol Sci</source><year>2004</year><volume>34</volume><issue>3</issue><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2004.01.001</pub-id><pub-id pub-id-type="pmid">15113590</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Hwang</surname><given-names>JK</given-names></name></person-group><article-title>Inhibitory effects of panduratin a on allergy-related mediator production in rat basophilic leukemia mast cells</article-title><source>Inflammation</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>1904</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1007/s10753-012-9513-y</pub-id><pub-id pub-id-type="pmid">22864999</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>W-M</given-names></name><name><surname>Lin</surname><given-names>T-J</given-names></name></person-group><article-title>Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation</article-title><source>Arch Immunol Ther Exp</source><year>2008</year><volume>56</volume><issue>6</issue><fpage>385</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1007/s00005-008-0041-2</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivaranjani</surname><given-names>N</given-names></name><name><surname>Venkata Rao</surname><given-names>S</given-names></name><name><surname>Rajeev</surname><given-names>G</given-names></name></person-group><article-title>Role of reactive oxygen species and antioxidants in atopic dermatitis</article-title><source>J Clin Diagnostic Res</source><year>2013</year><volume>7</volume><issue>12</issue><fpage>2683</fpage><lpage>2685</lpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>H</given-names></name><name><surname>Shibata</surname><given-names>R</given-names></name><name><surname>Ohshima</surname><given-names>Y</given-names></name><name><surname>Todoroki</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Ohta</surname><given-names>N</given-names></name><etal/></person-group><article-title>Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis</article-title><source>Life Sci</source><year>2003</year><volume>72</volume><issue>22</issue><fpage>2509</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(03)00145-0</pub-id><pub-id pub-id-type="pmid">12650859</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>XK</given-names></name></person-group><article-title>Oxidative stress in atopic dermatitis</article-title><source>Oxidative Med Cell Longev</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2016/2721469</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>MN</given-names></name><name><surname>Liza</surname><given-names>KF</given-names></name><name><surname>Sarwar</surname><given-names>MS</given-names></name><name><surname>Ahmed</surname><given-names>J</given-names></name><name><surname>Adnan</surname><given-names>MT</given-names></name><name><surname>Chowdhury</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Effect of lipid peroxidation, antioxidants, macro minerals and trace elements on eczema</article-title><source>Arch Dermatol Res</source><year>2015</year><volume>307</volume><issue>7</issue><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1007/s00403-015-1570-2</pub-id><pub-id pub-id-type="pmid">25967637</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakry</surname><given-names>OA</given-names></name><name><surname>Elshazly</surname><given-names>RMA</given-names></name><name><surname>Shoeib</surname><given-names>MAM</given-names></name><name><surname>Gooda</surname><given-names>A</given-names></name></person-group><article-title>Oxidative stress in alopecia areata: a case-control study</article-title><source>Am J Clin Dermatol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s40257-013-0036-6</pub-id><pub-id pub-id-type="pmid">23839259</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakawa</surname><given-names>T</given-names></name><name><surname>Deichmann</surname><given-names>KA</given-names></name><name><surname>Izuhara</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>XQ</given-names></name><name><surname>Adra</surname><given-names>CN</given-names></name><name><surname>Hopkin</surname><given-names>JM</given-names></name></person-group><article-title>Atopy and asthma: genetic variants of IL-4 and IL-13 signaling</article-title><source>Immunol Today</source><year>2000</year><volume>21</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0167-5699(99)01492-9</pub-id><pub-id pub-id-type="pmid">10652462</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>AA</given-names></name><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>B</given-names></name><name><surname>Rosenberg</surname><given-names>C</given-names></name><name><surname>Levitt</surname><given-names>J</given-names></name></person-group><article-title>Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis</article-title><source>Cutis</source><year>2006</year><volume>78</volume><issue>5</issue><fpage>357</fpage><lpage>363</lpage><?supplied-pmid 17186796?><pub-id pub-id-type="pmid">17186796</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Hong</surname><given-names>SI</given-names></name><name><surname>Jung</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Loganin protects against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells</article-title><source>Neurochem Int</source><year>2011</year><volume>58</volume><issue>4</issue><fpage>533</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2011.01.012</pub-id><pub-id pub-id-type="pmid">21241762</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Bae</surname><given-names>GS</given-names></name><name><surname>Jo</surname><given-names>IJ</given-names></name><name><surname>Choi</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>DG</given-names></name><name><surname>Shin</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Loganin protects against pancreatitis by inhibiting NF-&#x003ba;B activation</article-title><source>Eur J Pharmacol</source><year>2015</year><volume>765</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.09.019</pub-id><pub-id pub-id-type="pmid">26407655</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landete</surname><given-names>JM</given-names></name></person-group><article-title>Ellagitannins, ellagic acid and their derived metabolites: a review about source, metabolism, functions, and health</article-title><source>Food Res Int</source><year>2011</year><volume>44</volume><fpage>1150</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2011.04.027</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masamune</surname><given-names>A</given-names></name><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Kikuta</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name></person-group><article-title>Ellagic acid blocks activation of pancreatic stellate cells</article-title><source>Biochem Pharmacol</source><year>2005</year><volume>70</volume><issue>6</issue><fpage>869</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.06.008</pub-id><pub-id pub-id-type="pmid">16023081</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umesalma</surname><given-names>S</given-names></name><name><surname>Sudhandiran</surname><given-names>G</given-names></name></person-group><article-title>Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-alpha, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2010</year><volume>107</volume><issue>2</issue><fpage>650</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2010.00565.x</pub-id><pub-id pub-id-type="pmid">20406206</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>YT</given-names></name><name><surname>Tsai</surname><given-names>SH</given-names></name><name><surname>Lin-Shiau</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name></person-group><article-title>Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages</article-title><source>Carcinogenesis</source><year>1999</year><volume>20</volume><issue>10</issue><fpage>1945</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1093/carcin/20.10.1945</pub-id><pub-id pub-id-type="pmid">10506109</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parveen</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Saeed</surname><given-names>MK</given-names></name><name><surname>Dai</surname><given-names>R</given-names></name><name><surname>Ahamad</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>YH</given-names></name></person-group><article-title>Antiinflammatory and Analgesic activities of Thesium chinense turcz extracts and its major flavonoids, Kaempferol and Kaempferol-3-O-glucoside</article-title><source>Yakugaku Zasshi</source><year>2007</year><volume>127</volume><issue>8</issue><fpage>1275</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1248/yakushi.127.1275</pub-id><pub-id pub-id-type="pmid">17666881</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Jin</surname><given-names>GY</given-names></name><name><surname>Li</surname><given-names>GZ</given-names></name><name><surname>Yan</surname><given-names>GH</given-names></name></person-group><article-title>Cornuside suppresses lipopolysaccharide-induced inflammatory mediators by inhibiting nuclear factor-kappa B activation in RAW 264.7 macrophages</article-title><source>Biol Pharm Bull</source><year>2011</year><volume>34</volume><issue>7</issue><fpage>959</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1248/bpb.34.959</pub-id><pub-id pub-id-type="pmid">21719998</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orhan</surname><given-names>DD</given-names></name><name><surname>&#x000d6;z&#x000e7;elik</surname><given-names>B</given-names></name><name><surname>&#x000d6;zgen</surname><given-names>S</given-names></name><name><surname>Ergun</surname><given-names>F</given-names></name></person-group><article-title>Antibacterial, antifungal, and antiviral activities of some flavonoids</article-title><source>Microbiol Res</source><year>2010</year><volume>165</volume><issue>6</issue><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2009.09.002</pub-id><pub-id pub-id-type="pmid">19840899</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One. 2011;6(8).</mixed-citation></ref></ref-list></back></article>